Guangdong Taienkang Pharmaceutical Co. Ltd Net Asset Quality Index
Guangdong Taienkang Pharmaceutical Co. Ltd net asset quality index. Guangdong Taienkang Pharmaceutical Co. Ltd (301263) has a Net Asset Quality Index of 67.6% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.54 Billion minus total liabilities of CN¥820.32 Million yields net assets of CN¥1.72 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 301263 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Guangdong Taienkang Pharmaceutical Co. Ltd (2019–2025)
Net asset quality index of Guangdong Taienkang Pharmaceutical Co. Ltd from 2019 to 2025. This chart shows how Guangdong Taienkang Pharmaceutical Co. Ltd's Net Asset Quality Index has evolved across 7 annual periods from 2019 to 2025. As of June 2026, the index stands at 67.6%, representing net assets of CN¥1.72 Billion against total assets of CN¥2.54 Billion CNY. See Guangdong Taienkang Pharmaceutical Co. L shareholders equity for net asset value and shareholders' equity analysis.
Guangdong Taienkang Pharmaceutical Co. Ltd Net Asset Quality Index by Year (2019–2025)
Guangdong Taienkang Pharmaceutical Co. Ltd net asset quality index by year from 2019 to 2025. The table below presents the year-by-year Net Asset Quality Index for Guangdong Taienkang Pharmaceutical Co. Ltd from 2019 to 2025, covering 7 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Guangdong Taienkang Pharmaceutical Co. L (301263) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 72.0% | CN¥1.74 Billion | CN¥2.42 Billion | CN¥676.07 Million | ▼ -6.6 pp |
| 2024 | 78.6% | CN¥1.82 Billion | CN¥2.31 Billion | CN¥494.67 Million | ▼ -3.5 pp |
| 2023 | 82.1% | CN¥1.83 Billion | CN¥2.23 Billion | CN¥399.72 Million | ▼ -8.8 pp |
| 2022 | 90.9% | CN¥1.85 Billion | CN¥2.04 Billion | CN¥185.63 Million | ▲ +15.5 pp |
| 2021 | 75.4% | CN¥709.81 Million | CN¥941.52 Million | CN¥231.71 Million | ▲ +4.8 pp |
| 2020 | 70.6% | CN¥589.63 Million | CN¥834.75 Million | CN¥245.12 Million | ▼ -2.7 pp |
| 2019 | 73.3% | CN¥498.40 Million | CN¥679.56 Million | CN¥181.16 Million | — |